These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2106690)

  • 1. Management of von Willebrand's disease.
    Logan LJ
    Prog Clin Biol Res; 1990; 324():279-90. PubMed ID: 2106690
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of von Willebrand's disease.
    Logan LJ
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1079-94. PubMed ID: 1400073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of von Willebrand's disease.
    Mannucci PM
    J Intern Med Suppl; 1997; 740():129-32. PubMed ID: 9350194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of a hemorrhagic syndrome in severe von Willebrand disease in the presence of circulating anti-von-Willebrand-factor antibody].
    Monteagudo J; López Guillermo A; Castillo R
    Med Clin (Barc); 1988 May; 91(1):28-30. PubMed ID: 3139944
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelet-type von Willebrand's disease.
    Miller JL
    Clin Lab Med; 1984 Jun; 4(2):319-31. PubMed ID: 6437734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of von Willebrand's Disease.
    Mannucci PM
    N Engl J Med; 2004 Aug; 351(7):683-94. PubMed ID: 15306670
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical aspects of hemophilia and von Willebrand's disease.
    Ciavarella D; Counts RB
    Am J Med Technol; 1983 Dec; 49(12):850-4. PubMed ID: 6422754
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor.
    Grossmann RE; Geisen U; Schwender S; Keller F
    Thromb Haemost; 2000 Apr; 83(4):633-4. PubMed ID: 10780333
    [No Abstract]   [Full Text] [Related]  

  • 9. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet adhesion to collagen in subtypes of type I von Willebrand's disease is dependent on platelet von Willebrand factor.
    d'Alessio P; Zwaginga JJ; de Boer HC; Federici AB; Rodeghiero F; Castaman G; Mariani G; Mannucci PM; de Groot PG; Sixma JJ
    Thromb Haemost; 1990 Oct; 64(2):227-31. PubMed ID: 2125373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand's disease.
    Mannucci PM; Mari D
    Prog Clin Biol Res; 1984; 150():109-22. PubMed ID: 6431422
    [No Abstract]   [Full Text] [Related]  

  • 12. [Willebrand's disease and pregnancy. Fifteen cases].
    Depret-Mosser S; Marey A; Parquet-Gernez A; Theeten G; Goudemand J; Codaccioni X; Vinatier D; Monnier JC
    J Gynecol Obstet Biol Reprod (Paris); 1996; 25(4):405-10. PubMed ID: 8815140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Willebrand factor and von Willebrand's disease: a complex protein and a complex disease.
    Bona RD
    Ann Clin Lab Sci; 1989; 19(3):184-9. PubMed ID: 2499240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for the treatment of von Willebrand's disease.
    Sultan Y
    Prog Clin Biol Res; 1981; 72():149-62. PubMed ID: 6801684
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic effect of heat-treated factor VIII concentrates in von Willebrand's disease and related disorders: studies in platelet-type von Willebrand's disease].
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Takizawa S; Tamura M; Yamaguchi T; Wada K; Shibata A
    Rinsho Ketsueki; 1987 Dec; 28(12):2117-24. PubMed ID: 3133507
    [No Abstract]   [Full Text] [Related]  

  • 16. Control of hemorrhage and elimination of immune inhibitors in a female patient with a severe form of von Willebrand's disease.
    Marisavljević D; Elezović I; Miljić P; Radulović M; Stajić M
    Srp Arh Celok Lek; 1997; 125(9-10):311-6. PubMed ID: 9340805
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy in women with type 1 von Willebrand disease caused by heterozygosity for von Willebrand factor mutation C1130F.
    Castaman G; Eikenboom JC; Contri A; Rodeghiero F
    Thromb Haemost; 2000 Aug; 84(2):351-2. PubMed ID: 10959713
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa.
    Majumdar G; Phillips JK; Lavallee H; Savidge GF
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1035-7. PubMed ID: 8148477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.